Abstract
Thiol-containing antioxidant systems play an important role in regulating cellular redox homeostasis. Several anti-cancer agents act by targeting these systems by inducing the production of reactive oxygen species (ROS). Our earlier studies have shown that Eriocalyxin B (EriB), a diterpenoid isolated from Isodon eriocalyx, possesses anti-pancreatic tumour activities in vitro and in vivo. The present study further demonstrated that only thiol-containing antioxidants, N-acetylcysteine (NAC) or dithiothreitol (DTT), inhibited EriB-induced cytotoxicity and apoptosis. EriB suppressed the glutathione and thioredoxin antioxidant systems, thus increasing the intracellular ROS levels and regulating the MAPK, NFκB pathways. Treatment with EriB depleted the intracellular thiol-containing proteins in CAPAN-2 cells. In vivo studies also showed that EriB treatment (2.5 mg/kg) reduced the pancreatic tumour weights significantly in nude mice with increased superoxide levels. Taken together, our results shed important new light on the molecular mechanisms of EriB acting as an apoptogenic agent and its therapeutic potential for pancreatic cancer.
Keywords: Apoptosis, eriocalyxin B, pancreatic cancer, reactive oxygen species, thiols.
Current Molecular Medicine
Title:Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways
Volume: 14 Issue: 5
Author(s): L. Li, G.G.L. Yue, J.X. Pu, H.D. Sun, K.P. Fung, P.C. Leung, Q.B. Han, C.B.S. Lau and P.S. Leung
Affiliation:
Keywords: Apoptosis, eriocalyxin B, pancreatic cancer, reactive oxygen species, thiols.
Abstract: Thiol-containing antioxidant systems play an important role in regulating cellular redox homeostasis. Several anti-cancer agents act by targeting these systems by inducing the production of reactive oxygen species (ROS). Our earlier studies have shown that Eriocalyxin B (EriB), a diterpenoid isolated from Isodon eriocalyx, possesses anti-pancreatic tumour activities in vitro and in vivo. The present study further demonstrated that only thiol-containing antioxidants, N-acetylcysteine (NAC) or dithiothreitol (DTT), inhibited EriB-induced cytotoxicity and apoptosis. EriB suppressed the glutathione and thioredoxin antioxidant systems, thus increasing the intracellular ROS levels and regulating the MAPK, NFκB pathways. Treatment with EriB depleted the intracellular thiol-containing proteins in CAPAN-2 cells. In vivo studies also showed that EriB treatment (2.5 mg/kg) reduced the pancreatic tumour weights significantly in nude mice with increased superoxide levels. Taken together, our results shed important new light on the molecular mechanisms of EriB acting as an apoptogenic agent and its therapeutic potential for pancreatic cancer.
Export Options
About this article
Cite this article as:
Li L., Yue G.G.L., Pu J.X., Sun H.D., Fung K.P., Leung P.C., Han Q.B., Lau C.B.S. and Leung P.S., Eriocalyxin B-Induced Apoptosis in Pancreatic Adenocarcinoma Cells Through Thiol-Containing Antioxidant Systems and Downstream Signalling Pathways, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603102459
DOI https://dx.doi.org/10.2174/1566524014666140603102459 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets Quantitative Structure-Wavelength Relationship Modeling of Porphin -Derivative Photosensitizers
Combinatorial Chemistry & High Throughput Screening Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging CEBP Epigenetic Dysregulation as a Drug Target for the Treatment of Hematologic and Gynecologic Malignancies
Current Drug Targets IAP Proteins Antagonist: An Introduction and Chemistry of Smac Mimetics under Clinical Development
Current Medicinal Chemistry STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry A Nanotechnology-based Strategy to Increase the Efficiency of Cancer Diagnosis and Therapy: Folate-conjugated Gold Nanoparticles
Current Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) New Strategies for Metabolic Support in Cancer
Current Nutrition & Food Science Signal Transducer and Activator of Transcription 3 Signaling Pathway: A Potential Target in Sarcoma Treatment
Current Enzyme Inhibition Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Acid-extrusion from Tissue: The Interplay Between Membrane Transporters and pH Buffers
Current Pharmaceutical Design A Review of Fish Lectins
Current Protein & Peptide Science Recent Advances in Bone Graft Technologies
Recent Patents on Biomedical Engineering (Discontinued)